Log in

NASDAQ:SAGE - SAGE Therapeutics Stock Price, Forecast & News

$64.45
-2.69 (-4.01 %)
(As of 02/26/2020 02:12 AM ET)
Today's Range
$63.70
Now: $64.45
$67.63
50-Day Range
$64.45
MA: $70.51
$77.24
52-Week Range
$56.50
Now: $64.45
$193.56
Volume702,277 shs
Average Volume716,884 shs
Market Capitalization$3.34 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.43
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAGE
CUSIPN/A
Phone617-299-8380

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.27 million
Book Value$18.41 per share

Profitability

Net Income$-372,880,000.00
Net Margins-12,931.34%

Miscellaneous

Employees637
Market Cap$3.34 billion
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive SAGE News and Ratings via Email

Sign-up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.


SAGE Therapeutics (NASDAQ:SAGE) Frequently Asked Questions

What is SAGE Therapeutics' stock symbol?

SAGE Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

How were SAGE Therapeutics' earnings last quarter?

SAGE Therapeutics Inc (NASDAQ:SAGE) announced its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($3.48) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($3.41) by $0.07. The biopharmaceutical company had revenue of $3.57 million for the quarter, compared to analysts' expectations of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The business's quarterly revenue was up 35600.0% on a year-over-year basis. During the same period last year, the company posted ($2.63) earnings per share. View SAGE Therapeutics' Earnings History.

When is SAGE Therapeutics' next earnings date?

SAGE Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for SAGE Therapeutics.

How can I listen to SAGE Therapeutics' earnings call?

SAGE Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for SAGE?

20 brokerages have issued 12-month price objectives for SAGE Therapeutics' shares. Their forecasts range from $63.00 to $263.00. On average, they expect SAGE Therapeutics' share price to reach $123.78 in the next twelve months. This suggests a possible upside of 92.1% from the stock's current price. View Analyst Price Targets for SAGE Therapeutics.

What is the consensus analysts' recommendation for SAGE Therapeutics?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAGE Therapeutics in the last year. There are currently 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SAGE Therapeutics.

Has SAGE Therapeutics been receiving favorable news coverage?

News stories about SAGE stock have trended extremely positive this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. SAGE Therapeutics earned a daily sentiment score of 5.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for SAGE Therapeutics.

Are investors shorting SAGE Therapeutics?

SAGE Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totalling 7,050,000 shares, an increase of 15.6% from the December 31st total of 6,100,000 shares. Based on an average daily volume of 1,070,000 shares, the short-interest ratio is currently 6.6 days. Currently, 13.9% of the shares of the company are short sold. View SAGE Therapeutics' Current Options Chain.

Who are some of SAGE Therapeutics' key competitors?

What other stocks do shareholders of SAGE Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SAGE Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), salesforce.com (CRM), Gilead Sciences (GILD) and GW Pharmaceuticals PLC- (GWPH).

Who are SAGE Therapeutics' key executives?

SAGE Therapeutics' management team includes the folowing people:
  • Dr. Jeffrey M. Jonas, CEO, Pres & Director (Age 66)
  • Ms. Kimi E. Iguchi, CFO & Treasurer (Age 57)
  • Dr. Albert J. Robichaud, Chief Scientific Officer (Age 58)
  • Ms. Anne Marie Cook, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Mr. Michael Cloonan, Chief Bus. Officer (Age 48)

Who are SAGE Therapeutics' major shareholders?

SAGE Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Capital International Investors (7.36%), Janus Henderson Group PLC (4.66%), State Street Corp (3.20%), Victory Capital Management Inc. (2.05%) and Franklin Resources Inc. (1.69%). Company insiders that own SAGE Therapeutics stock include Albert Robichaud, Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Michael Cloonan, Stephen Kanes and Steven M Paul. View Institutional Ownership Trends for SAGE Therapeutics.

Which institutional investors are selling SAGE Therapeutics stock?

SAGE stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alliancebernstein L.P., Franklin Resources Inc., Casdin Capital LLC, Fiera Capital Corp, New York State Common Retirement Fund, Tocqueville Asset Management L.P. and Oak Ridge Investments LLC. Company insiders that have sold SAGE Therapeutics company stock in the last year include Anne Marie Cook, James M Frates, Jeffrey M Jonas, Kimi Iguchi, Michael Cloonan and Steven M Paul. View Insider Buying and Selling for SAGE Therapeutics.

Which institutional investors are buying SAGE Therapeutics stock?

SAGE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Victory Capital Management Inc., Janus Henderson Group PLC, Boxer Capital LLC, Victory Capital Management Inc., EcoR1 Capital LLC, Capital International Investors and Zevenbergen Capital Investments LLC. Company insiders that have bought SAGE Therapeutics stock in the last two years include Albert Robichaud and Jeffrey M Jonas. View Insider Buying and Selling for SAGE Therapeutics.

How do I buy shares of SAGE Therapeutics?

Shares of SAGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is SAGE Therapeutics' stock price today?

One share of SAGE stock can currently be purchased for approximately $64.45.

How big of a company is SAGE Therapeutics?

SAGE Therapeutics has a market capitalization of $3.34 billion and generates $90.27 million in revenue each year. The biopharmaceutical company earns $-372,880,000.00 in net income (profit) each year or ($8.08) on an earnings per share basis. SAGE Therapeutics employs 637 workers across the globe.View Additional Information About SAGE Therapeutics.

What is SAGE Therapeutics' official website?

The official website for SAGE Therapeutics is http://www.sagerx.com/.

How can I contact SAGE Therapeutics?

SAGE Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-299-8380 or via email at [email protected]


MarketBeat Community Rating for SAGE Therapeutics (NASDAQ SAGE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  550 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  873
MarketBeat's community ratings are surveys of what our community members think about SAGE Therapeutics and other stocks. Vote "Outperform" if you believe SAGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Beige Book

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel